Management of Psychomotor Agitation in Elderly Patients with Parkinson's Disease

Introduction to Quetiapine Therapy

The American College of Cardiology is not relevant here, however, quetiapine can be increased with caution up to 50 mg per day in elderly patients with Parkinson's disease and psychomotor agitation, maintaining the lowest effective dose 1
Quetiapine is a suitable option for treating psychomotor agitation in patients with Parkinson's disease because it is less likely to cause extrapyramidal symptoms compared to other atypical antipsychotics 1

The initial dosage of quetiapine should be increased gradually, by 12.5-25 mg every 3-7 days, based on clinical response and tolerability, with a maximum recommended dose of 50 mg per day for elderly patients with Parkinson's disease 1

Haloperidol should not be used in patients with Parkinson's disease due to the high risk of extrapyramidal symptoms 1
Patients on quetiapine should be monitored for orthostatic hypotension, a common side effect 1
Sedation, which can be beneficial for sleep disturbances, should also be monitored 1
Vertigo is another potential side effect that requires monitoring 1
The dose should be reduced in patients with hepatic impairment 1
Quetiapine is preferably administered in two daily doses 1

When combining quetiapine with benzodiazepines, such as clonazepam, caution should be exercised due to the potential for increased sedation or respiratory depression 1
Lower doses of both medications should be considered when used in combination 1

The severity of psychomotor agitation should be assessed, with gradual increase in dosage for moderate to severe cases 1, 2
The response to the increased dosage should be evaluated after 5-7 days, with further adjustments as necessary and tolerated 2
Close monitoring of motor function, blood pressure, cognitive status, and sleep quality is essential during dosage adjustments 1, 2